

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 270751744 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 16, 2004 Signature: _____

(John Tessman)

PATENT
Docket No. 252312005706

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen M. COUTTS et al.

Serial No.: 09/753,350

Filing Date: December 29, 2000

For: CONJUGATES OF T CELL EPITOPE
DEFICIENT IMMUNOGEN ANALOGS
FOR HUMORAL ANERGY AND
CHEMICALLY DEFINED NON-
POLYMERIC VALENCY PLATFORM
MOLECULES

Examiner: P. Huynh

Group Art Unit: 1644

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

12/22/2004 CNGUYEN 00000093 031952 09753350

01 FC:1806 180.00 DA

/

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;


(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **252312005706**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 16, 2004


Respectfully submitted,

By


John W. Tessman

Registration No.: 43,949

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304
(650) 813-5786



ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/753,350
				Filing Date	December 29, 2000
				First Named Inventor	Stephen M. COUTTS
				Art Unit	1644
				Examiner Name	P. Huynh
Sheet	1	of	1	Attorney Docket Number	252312005706

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,234,563	11-18-1980	Rippe	
	2.	US-4,399,121	08-16-1983	Albarella et al.	
	3.	US-4,558,120	12-10-1985	Tomalia et al.	
	4.	US-4,568,737	02-04-1986	Tomalia et al.	
	5.	US-4,822,594	04-18-1989	Gibby	
	6.	US-5,135,737-A	08-04-1992	Keana	
	7.	US-5,219,564-A	06-15-1993	Zalipsky et al.	
	8.	US-5,229,366-A	07-20-1993	Tsukada et al.	
	9.	US-5,229,490-A	07-20-1993	Tam	
	10.	US-5,338,532-A	08-16-1994	Tomalia et al.	
	11.	US-6,011,020-A	01-04-2000	Gold et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	12.	EP-0 457 438-A2	11-21-1991	CellTech Limited		
	13.	DD-02 87 950-A5	03-14-1991			T ⁷
	14.	WO-88/01178-A1	02-25-1988	The Dow Chemical Company		
	15.	WO-90/10448-A2	09-30-1990	Genentech, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16.	Aharoni, S.M. et al. (1982). "Size and Solution Properties of Globular <i>tert</i> -Butyloxycarbonyl-poly(α,ϵ -L-lysine)," <i>Macromolecules</i> 15(4):1093-1098.	
	17.	Hudecz, F. et al. (1992). "Synthesis, Conformation, Biodistribution, and in Vitro Cytotoxicity of Daunomycin-Branched Polypeptide Conjugates," <i>Bioconjugate Chem.</i> 3(1):49-57.	
	18.	Hudecz, F. et al. (1993). "Influence of Carrier on Biodistribution and in Vitro Cytotoxicity of Methotrexate-Branched Polypeptide Conjugates," <i>Bioconjugate Chem.</i> 4(1):25-33.	
	19.	McLean, G.W. et al. (1992). "Rapid Attachment of a Helper T Cell Epitope to Branched Peptides by Fragment Condensation to Give Enhanced Immunogenicity," <i>Journal of Immunological Methods</i> 155:113-120.	
	20.	Peacock, J.S. et al. (1979). "Antigenic Stimulation of Lymphocytes. II. Immunogenicity of Dinitrophenyl-Polyethylene Oxide Antigens," <i>Cellular Immunology</i> 43:382-387.	
	21.	Tam, J.P. (August 1988). "Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide Systems," <i>Proc. Natl. Acad. Sci. USA</i> 85:5409-5413.	
	22.	Tomalia, D.A. et al. (1985). "A New Class of Polymers: Starburst-Dendritic Macromolecules," <i>Polymer Journal</i> 17(1):117-132.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa-943023